<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant selection in heparin-induced thrombocytopenia (HIT; suspected or confirmed)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant selection in heparin-induced thrombocytopenia (HIT; suspected or confirmed)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Anticoagulant selection in heparin-induced thrombocytopenia (HIT; suspected or confirmed)</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Anticoagulant</td> <td class="subtitle1">Features affecting selection</td> <td class="subtitle1">Mechanism, administration, and monitoring</td> </tr> <tr> <td>Argatroban</td> <td> <ul> <li>Short-acting</li> <li>Can be used in CKD; no dose adjustment needed</li> <li>Eliminated hepatically; dose adjustment needed in liver impairment</li> <li>Can be used in pregnancy</li> <li>Use in breastfeeding unknown</li> </ul> </td> <td> <ul> <li>Parenteral direct thrombin inhibitor</li> <li>Administered by continuous intravenous infusion</li> <li>Monitored and adjusted by aPTT; obtain aPTT prior to initiation, two hours after starting infusion, and after dose changes</li> <li>Half-life approximately 40 to 50 minutes (prolonged to approximately 180 minutes in hepatic impairment)</li> <li>Prolongs the PT/INR</li> <li>No reversal agent (but effect is rapidly reversed upon discontinuation)</li> <li>Expensive</li> </ul> </td> </tr> <tr> <td>Bivalirudin</td> <td> <ul> <li>Short-acting</li> <li>Eliminated by the kidney; dose adjustment needed in CKD</li> <li>Can be used in liver impairment; no dose adjustment is needed</li> <li>Multi-organ failure in critical illness; dose adjustment is needed</li> <li>Can be used in pregnancy</li> <li>Use in breastfeeding unknown</li> </ul> </td> <td> <ul> <li>Parenteral direct thrombin inhibitor</li> <li>Administered by continuous intravenous infusion</li> <li>Monitored and adjusted by aPTT; obtain aPTT prior to infusion, two hours after starting infusion, and after dose changes</li> <li>Half-life approximately 25 minutes (prolonged to approximately 3.5 hours in ESKD)</li> <li>Prolongs the PT/INR, less so than argatroban</li> <li>No reversal agent (but effect is rapidly reversed upon discontinuation)</li> <li>Expensive</li> </ul> </td> </tr> <tr> <td>Danaparoid (not available in United States)</td> <td> <ul> <li>Parenteral agent; may be given subcutaneously following initial intravenous bolus</li> <li>Eliminated by the kidney; dose adjustment needed in CKD</li> <li>Can be used in liver impairment; no dose adjustment is needed</li> <li>Can be used in pregnancy</li> <li>Can be used in breastfeeding</li> </ul> </td> <td> <ul> <li>Parenteral inhibitor of thrombin and factor Xa (indirect, heparinoid, derived from porcine intestine)</li> <li>Administered intravenously or subcutaneously (intravenous dosing preferred if an invasive procedure is likely to be needed)</li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed*</li> <li>Half-life (anti-factor Xa activity) is approximately 25 hours; prolonged to 29 to 35 hours in CKD</li> <li>No reversal agent</li> </ul> </td> </tr> <tr> <td>Fondaparinux</td> <td> <ul> <li>Subcutaneous agent</li> <li>Eliminated by the kidney; dose adjustment is needed for CrCl 30 to 50 mL/minute and should not be used if CrCl is &lt;30 mL/minute</li> <li>Can be used in liver impairment; no dose adjustment is needed</li> <li>Not suitable if likely to undergo urgent invasive procedure due to long half-life</li> <li>Can be used in pregnancy</li> </ul> </td> <td> <ul> <li>Parenteral inhibitor of factor Xa (indirect)</li> <li>Administered subcutaneously, once per day</li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed*</li> <li>Half-life 17 to 21 hours; prolonged in renal impairment, older adults, and low body weight</li> <li>Possible reversal with andexanet alfa</li> </ul> </td> </tr> <tr> <td>Apixaban</td> <td> <ul> <li>Oral agent</li> <li>Eliminated by the kidney and liver (less dependent on kidney function than other DOACs); no dose adjustment is needed for CrCl ≥25 mL/minute or mild to moderate hepatic impairment</li> <li>Do not use if CrCl &lt;25 mL/minute, serum creatinine &gt;2.5 mg/dL, dialysis-dependent, or severe hepatic impairment</li> <li>Subject to CYP3A4 and P-gp drug interactions</li> <li>Use in pregnancy and breastfeeding unknown</li> </ul> </td> <td> <ul> <li>Oral direct factor Xa inhibitor</li> <li>Administered orally, twice-daily dosing (higher initial dose for VTE treatment)</li> <li>Half-life approximately 12 hours</li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed*</li> <li>Reversal agent (andexanet alfa or PCC)</li> <li>Not dialyzable</li> </ul> </td> </tr> <tr> <td>Dabigatran</td> <td> <ul> <li>Oral agent</li> <li>Mostly eliminated by the kidney; no dose adjustment needed for CrCl &gt;30 mL/minute or liver <span class="nowrap_whitespace">impairment<sup>¶</sup></span></li> <li>Do not use if CrCl ≤30 mL/minute or dialysis-dependent</li> <li>Subject to P-gp drug interactions</li> <li>Use in pregnancy and breastfeeding unknown</li> </ul> </td> <td> <ul> <li>Oral direct thrombin inhibitor</li> <li>Administered orally, twice-daily dosing (initial parenteral agent for VTE treatment)</li> <li>Half-life 12 to 17 hours; prolonged up to 28 hours in severe renal impairment</li> <li>No routine coagulation test monitoring; refer to UpToDate for monitoring in selected cases</li> <li>Reversal agent (idarucizumab)</li> </ul> </td> </tr> <tr> <td>Edoxaban</td> <td> <ul> <li>Oral agent</li> <li>Eliminated by the kidney and liver; no dose adjustment required for CrCl &gt;50 mL/minute or mild liver impairment</li> <li>Dose adjustment is needed for CrCl 15 to 50 mL/minute</li> <li>Do not use if CrCl ≤15 mL/minute or &gt;95 mL/minute, dialysis-dependent, or moderate to severe liver impairment</li> <li>Dose adjustment needed for body weight ≤60 kg</li> <li>Subject to CYP3A4 and P-gp drug interactions</li> <li>Use in pregnancy and breastfeeding unknown</li> </ul> </td> <td> <ul> <li>Oral direct factor Xa inhibitor</li> <li>Administered orally, once-daily dosing (initial parenteral agent for VTE treatment)</li> <li>Half-life 10 to 14 hours; prolonged in renal impairment</li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed*</li> <li>Reversal agent (andexanet alfa or PCC)</li> </ul> </td> </tr> <tr> <td>Rivaroxaban</td> <td> <ul> <li>Eliminated by the kidney and liver; no dose adjustment is needed for CrCl &gt;30 mL/minute or mild liver impairment</li> <li>Do not use if CrCl ≤30 mL/minute, dialysis-dependent, or moderate to severe hepatic impairment</li> <li>Subject to CYP3A4 and P-gp drug interactions</li> <li>Use in pregnancy and breastfeeding unknown</li> </ul> </td> <td> <ul> <li>Oral direct factor Xa inhibitor</li> <li>Administered orally once-daily dosing (initial twice-daily dosing for VTE treatment)</li> <li>Half-life 5 to 9 hours</li> <li>No routine monitoring; anti-factor Xa activity can be monitored if needed*</li> <li>Reversal agent (andexanet alfa or PCC)</li> </ul> </td> </tr> <tr> <td>Warfarin</td> <td> <ul> <li><strong>Cannot</strong> be used until stable anticoagulation with another non-heparin anticoagulant has been established and the platelet count has normalized or returned to baseline</li> <li>Can be used in severe kidney or liver impairment; monitor INR closely</li> <li>Many drug and dietary interactions</li> <li>Can be used in patients with a mechanical heart valve</li> <li>Teratogen: Avoid in first trimester of pregnancy unless benefits outweigh risks (eg, mechanical heart valve)</li> </ul> </td> <td> <ul> <li>Oral vitamin K antagonist, interferes with synthesis of thrombin and factors VII, IX, and X</li> <li>Administered orally, once-daily dosing with regular monitoring and dose adjustments based on the PT/INR</li> <li>Requires at least five consecutive days of overlapping non-heparin anticoagulant that is continued until the INR is therapeutic</li> <li>If transitioning from argatroban to warfarin, refer to institutional guidelines for INR target as both agents elevate the INR</li> <li>Reversal agent (vitamin K and PCC)</li> <li>Inexpensive</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>Refer to UpToDate for details of the clinical evaluation for HIT, duration of non-heparin anticoagulant therapy, and other considerations. For patients with a thromboembolic event, DOACs require initial higher dosing or a parenteral agent:</p>
<ul class="decimal_heading">
<li>Dabigatran or edoxaban – Must be preceded by five days of a parenteral anticoagulant.</li>
<li>Apixaban or rivaroxaban – Initial dosing is higher.</li>
</ul>
<p class="extra_spacing_top">For agents that inhibit factor Xa, anti-factor Xa testing may be useful in selected patients (prior to urgent neurosurgery, extremes of body weight, CKD). If anti-factor Xa testing is used, it must be calibrated for the specific anticoagulant. Anti-factor-Xa activity calibrated for fondaparinux or danaparoid is not available in many clinical settings.</p></div><div class="graphic_footnotes"><p>HIT: heparin-induced thrombocytopenia; CKD: chronic kidney disease; aPTT: activated partial thromboplastin time; PT: prothrombin time; INR: international normalized ratio; ESKD: end-stage kidney disease; factor Xa: activated factor X; DOACs: direct-acting oral anticoagulants; CrCl: creatinine clearance; VTE: venous thromboembolism; PCC: prothrombin complex concentrate.</p>
<p>* If anti-factor Xa monitoring is used, it must be done using an assay calibrated for the specific drug the patient is taking.</p>
¶ In some countries other than the United States, the approved product information recommends a dose reduction in patients with moderately impaired kidney function and elevated risk of bleeding.</div><div id="graphicVersion">Graphic 115506 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
